Prestige BioPharma

Prestige Biopharma is one of the fastest-growing biopharmaceutical companies, focusing on the development of biosimilars, first-class antibody drugs, and infectious disease vaccines. With decades of R&D and operational experience in drug discovery, we accelerate the development and commercialization of future biologics in a coordinated manner based on our proprietary technology and scientific capabilities.Prestige is committed to becoming a global innovator by developing first-class antibody therapies, including PBP1510 anti-PAUF mAb (INN-Ulenistamab) for pancreatic cancer, which recently received orphan drug designation from the FDA, EMA, and MFDS. Prestige has a rich portfolio of biosimilars at various stages, including HD201 Trastuzumab under EU EMA MAA review, HD204 Bevacizumab in global Phase III, and PBP1502 Adalimumab in Phase I, aiming to provide affordable and high-quality medicines to those in need.